SCHEMBL5149773

SCHEMBL5149773

COC(=O)c1ccc(N(C)CC2CCCN2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.45
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ UCHL1 P09936 2/20 0.43
▸ USP30 Q70CQ3 1/20 0.43
▸ STAT6 P42226 1/20 0.42
▸ DPP4 P27487 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ NOTUM Q6P988 1/20 0.40
▸ FPR3 P25089 1/20 0.40
▸ FPR2 P25090 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KDM1A O60341 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ ATM Q13315 2/20 0.39
▸ CHEK2 O96017 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3039427 0.97 HDAC1 (0.43) NPC1HDAC1HDAC6UCHL1USP30
SCHEMBL3025799 0.85 LTA4H (0.45) NPC1HDAC1HDAC6UCHL1USP30
SCHEMBL2390642 0.83 KDM1A (0.42) NPC1STAT6OPRD1FPR3FPR2
SCHEMBL3040839 0.82 LTA4H (0.46) NPC1HDAC1HDAC6UCHL1USP30
SCHEMBL21834842 0.82 NPC1 (0.48) NPC1HDAC1HDAC6UCHL1USP30
SCHEMBL5155000 0.81 HPGD (0.44) NPC1UCHL1USP30MEN1KMT2A
SCHEMBL5150103 0.81 NPC1 (0.52) NPC1HDAC1HDAC6UCHL1USP30
SCHEMBL5151622 0.81 NPC1 (0.47) NPC1UCHL1USP30CHEK2
SCHEMBL5152275 0.80 NPC1 (0.46) NPC1HDAC1HDAC6UCHL1USP30
SCHEMBL3042734 0.79 HDAC1 (0.46) NPC1HDAC1HDAC6UCHL1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 NPC1 2939/4885HDAC1 1188/4885HDAC6 1240/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 NPC1 3300/4885HDAC1 1277/4885HDAC6 1340/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 NPC1 2981/4885HDAC1 1199/4885HDAC6 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback